These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 17561988)

  • 1. Nitric oxide inhibition rapidly increases blood pressure with no change in outcome in cardiogenic shock: the TRIUMPH trial.
    Salem R; Mebazaa A
    Crit Care; 2007; 11(3):136. PubMed ID: 17561988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial.
    ; Alexander JH; Reynolds HR; Stebbins AL; Dzavik V; Harrington RA; Van de Werf F; Hochman JS
    JAMA; 2007 Apr; 297(15):1657-66. PubMed ID: 17387132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of 30-day mortality in patients with refractory cardiogenic shock following acute myocardial infarction despite a patent infarct artery.
    Katz JN; Stebbins AL; Alexander JH; Reynolds HR; Pieper KS; Ruzyllo W; Werdan K; Geppert A; Dzavik V; Van de Werf F; Hochman JS;
    Am Heart J; 2009 Oct; 158(4):680-7. PubMed ID: 19781431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of vasopressin on hemodynamics in patients with refractory cardiogenic shock complicating acute myocardial infarction.
    Jolly S; Newton G; Horlick E; Seidelin PH; Ross HJ; Husain M; Dzavik V
    Am J Cardiol; 2005 Dec; 96(12):1617-20. PubMed ID: 16360345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemodynamic effects of levosimendan in acute myocardial infarction complicated by cardiogenic shock and high systemic vascular resistance.
    Tsagalou EP; Kanakakis J; Anastasiou-Nana MI; Drakos SG; Ntalianis AS; Malliaras K; Lazaris N; Katsaros F; Nanas JN
    Acute Card Care; 2009; 11(2):99-106. PubMed ID: 19353405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of nitric oxide synthase inhibition on haemodynamics and outcome of patients with persistent cardiogenic shock complicating acute myocardial infarction: a phase II dose-ranging study.
    Dzavík V; Cotter G; Reynolds HR; Alexander JH; Ramanathan K; Stebbins AL; Hathaway D; Farkouh ME; Ohman EM; Baran DA; Prondzinsky R; Panza JA; Cantor WJ; Vered Z; Buller CE; Kleiman NS; Webb JG; Holmes DR; Parrillo JE; Hazen SL; Gross SS; Harrington RA; Hochman JS;
    Eur Heart J; 2007 May; 28(9):1109-16. PubMed ID: 17459901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tilarginine in patients with acute myocardial infarction and cardiogenic shock.
    Kielstein JT; Sydow K; Thum T
    JAMA; 2007 Sep; 298(9):971; author reply 972-3. PubMed ID: 17785641
    [No Abstract]   [Full Text] [Related]  

  • 8. Cardiogenic shock: the role of inflammation.
    Shpektor A
    Acute Card Care; 2010 Dec; 12(4):115-8. PubMed ID: 21039083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A blinded, randomized, controlled trial of three doses of high-dose insulin in poison-induced cardiogenic shock.
    Cole JB; Stellpflug SJ; Ellsworth H; Anderson CP; Adams AB; Engebretsen KM; Holger JS
    Clin Toxicol (Phila); 2013 May; 51(4):201-7. PubMed ID: 23530460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tilarginine in patients with acute myocardial infarction and cardiogenic shock.
    Teerlink T
    JAMA; 2007 Sep; 298(9):971-2; author reply 972-3. PubMed ID: 17785640
    [No Abstract]   [Full Text] [Related]  

  • 11. A prospective, randomized, crossover pilot study of inhaled nitric oxide versus inhaled prostacyclin in heart transplant and lung transplant recipients.
    Khan TA; Schnickel G; Ross D; Bastani S; Laks H; Esmailian F; Marelli D; Beygui R; Shemin R; Watson L; Vartapetian I; Ardehali A
    J Thorac Cardiovasc Surg; 2009 Dec; 138(6):1417-24. PubMed ID: 19931670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcome and its predictors among patients with ST-segment elevation myocardial infarction complicated by shock: insights from the GUSTO-I trial.
    Singh M; White J; Hasdai D; Hodgson PK; Berger PB; Topol EJ; Califf RM; Holmes DR
    J Am Coll Cardiol; 2007 Oct; 50(18):1752-8. PubMed ID: 17964038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levosimendan in patients with acute myocardial ischaemia undergoing emergency surgical revascularization.
    Lehmann A; Kiessling AH; Isgro F; Zeitler C; Thaler E; Boldt J
    Eur J Anaesthesiol; 2008 Mar; 25(3):224-9. PubMed ID: 17892614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiogenic shock: basics and clinical considerations.
    Gowda RM; Fox JT; Khan IA
    Int J Cardiol; 2008 Jan; 123(3):221-8. PubMed ID: 18037513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Slow infusion of calcium channel blockers compared with intravenous adenosine in the emergency treatment of supraventricular tachycardia.
    Lim SH; Anantharaman V; Teo WS; Chan YH
    Resuscitation; 2009 May; 80(5):523-8. PubMed ID: 19261367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The tragedy of TRIUMPH for nitric oxide synthesis inhibition in cardiogenic shock: where do we go from here?
    Bailey A; Pope TW; Moore SA; Campbell CL
    Am J Cardiovasc Drugs; 2007; 7(5):337-45. PubMed ID: 17953472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with the arginase inhibitor N(omega)-hydroxy-nor-L-arginine improves vascular function and lowers blood pressure in adult spontaneously hypertensive rat.
    Bagnost T; Berthelot A; Bouhaddi M; Laurant P; André C; Guillaume Y; Demougeot C
    J Hypertens; 2008 Jun; 26(6):1110-8. PubMed ID: 18475148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nitric oxide synthase inhibitors in cardiogenic shock: present and future.
    Kaluski E; Uriel N; Milo-Cotter O; Klapholz M
    Future Cardiol; 2008 Mar; 4(2):183-9. PubMed ID: 19804295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Orthostatic responses to nitric oxide synthase inhibition in persons with tetraplegia.
    Wecht JM; Radulovic M; Lafountaine MF; Rosado-Rivera D; Zhang RL; Bauman WA
    Arch Phys Med Rehabil; 2009 Aug; 90(8):1428-34. PubMed ID: 19651280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years.
    Kisicki JC; Fiske K; Lyne A
    Clin Ther; 2007 Sep; 29(9):1967-79. PubMed ID: 18035196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.